Drug Trial News

RSS

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

AstraZeneca today reported new Phase I extended follow-up data on osimertinib in both first- and second-line treatment of patients with non-small cell lung cancer (NSCLC), at the European Lung Cancer Conference (ELCC) 2016. Late-breaker presentations reinforced the efficacy and safety profile for osimertinib previously seen in the AURA clinical trials programme.

15 Apr 2016

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).

15 Apr 2016

Binding Site to collarborate in iStopMM (Iceland Screens, Treats or Prevents Multiple Myeloma) trial

Binding Site is proud to be a key collaborator with Prof Sigurdur Kristinsson of the University of Iceland in his pivotal MGUS screening study for the forthcoming iStopMM (Iceland Screens, Treats or Prevents Multiple Myeloma) trial.

From Binding Site 14 Apr 2016

New clinical data highlights potential of AB-PA01 to treat P. aeruginosa infections in CF patients

AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix AB-PA01.

13 Apr 2016

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

13 Apr 2016

Novel antibiotics to overcome antibacterial resistance

Small and innovative pharmaceutical companies, with products in early stages of development, presented some of their novel approaches and antimicrobial therapies under development during a dedicated session at the annual congress (ECCMID) of the European Society of Clinical Microbiology and Infectious Diseases(ESCMID) in Amsterdam.

13 Apr 2016

Pooled analysis from seven clinical studies demonstrates consistent efficacy for ceftazidime-avibactam in the treatment of multi-drug resistant gram-negative bacteria

AstraZeneca has presented positive data demonstrating the efficacy of the investigational antibiotic, ceftazidime-avibactam (CAZ-AVI), in treating patients with ceftazidime-resistant Gram-negative infections, which are increasingly resistant to most available antibiotics, often precipitating the need for clinicians to reach for agents previously reserved for last-line use.

12 Apr 2016

AstraZeneca, MedImmune to present new clinical trial and scientific data on lung cancer treatments at ELCC 2016

AstraZeneca and its global biologics research and development arm, MedImmune, will report new clinical trial and scientific data from their industry-leading lung cancer franchise of marketed and pipeline medicines at the European Lung Cancer Conference in Geneva, Switzerland, 13 -16 April 2016.

11 Apr 2016

Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

Ludwig Cancer Research and the Cancer Research Institute have launched a Phase 1/2 clinical trial of combination immunotherapy for advanced ovarian cancer. The international, multicenter trial is led by George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne and Brad Monk, director of Gynecologic Oncology at St. Joseph's Hospital and Medical Center.

7 Apr 2016

Wake Forest Baptist researchers looking for ways to keep older adults on their feet

There's no getting around it: Simply getting around is a major issue for older adults. "People are in nursing homes for two reasons, either they can't think or they can't walk," said Stephen Kritchevsky, Ph.D., director of the Sticht Center on Aging at Wake Forest Baptist Medical Center. North Carolina. "We're working very hard on the thinking part, and the walking part is equally important.

6 Apr 2016

Losmapimod drug fails to meet primary endpoint in clinical trial

Patients taking losmapimod, an anti-inflammatory drug currently being developed, for 12 weeks following a heart attack did not show improvements in the trial's primary endpoint, the rate of cardiovascular death, subsequent heart attack or urgent coronary revascularization, which includes placement of a stent or coronary artery bypass surgery, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

5 Apr 2016

Study elucidates potential benefits of antiarrhythmic drugs for out-of-hospital cardiac arrest patients

Paramedics often give heart rhythm stabilizing drugs to patients who are suffering out-of-hospital cardiac arrest when they fail to regain a stable heart rhythm after electrical shock treatment.

5 Apr 2016

Two common approaches to post-operative AF equally safe, effective

Cleveland Clinic researchers, as part of the Cardiothoracic Surgical Trials Network, have found that two common approaches to post-operative atrial fibrillation - rhythm control and rate control - are equally safe and effective.

5 Apr 2016

New stem cell therapy significantly improves outcomes in patients with severe heart failure

A new stem cell therapy significantly improved long-term health outcomes in patients with severe and end-stage heart failure in a study presented at the American College of Cardiology's 65th Annual Scientific Session.

5 Apr 2016

Investigational drug provides no improved protection to patients with contrast-induced acute kidney injury

Patients treated with CMX-2043--an investigational drug that has previously shown some ability to protect heart muscle from damage during stenting--saw no improved protection in their kidneys compared to placebo, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

5 Apr 2016

Evolocumab could be more effective than ezetimibe in lowering cholesterol in statin-intolerant patients

In the first major trial of its kind, Cleveland Clinic researchers used a blinded rechallenge with atorvastatin or placebo to objectively confirm the presence of muscle-related symptoms in patients with a history of intolerance to multiple statins and found that evolocumab (a PCSK9 inhibitor) was a more effective option to lower cholesterol than ezetimibe in these patients.

4 Apr 2016

Researchers compare lipid-lowering efficacy for two nonstatin therapies in statin-intolerant patients

Steven E. Nissen, M.D., of the Cleveland Clinic, and colleagues identified patients with muscle-related adverse effects from statins and compared lipid-lowering efficacy for two nonstatin therapies, ezetimibe and evolocumab. The study was published online by JAMA, and is being released to coincide with its presentation at the American College of Cardiology's 65th Annual Scientific Session & Expo.

4 Apr 2016

Investigational drug abaloparatide-SC may help increase bone mineral density in postmenopausal women

The investigational drug abaloparatide-SC (subcutaneous) may help increase bone mineral density in postmenopausal women and reduce their risk of fracture, new industry-sponsored research suggests. The results of the subgroup analysis within the ACTIVE clinical trial will be presented Friday, April 1, at ENDO 2016, the annual meeting of the Endocrine Society in Boston.

4 Apr 2016

Cholesterol drug evacetrapib fails to reduce risk of cardiovascular events

Despite lowering low-density lipoprotein (LDL), known as "bad" cholesterol, while markedly increasing levels of high-density lipoprotein (HDL), or "good" cholesterol, a large clinical trial to investigate the cholesterol drug evacetrapib was discontinued early after a preliminary analysis showed it did not reduce rates of major adverse cardiovascular events, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

4 Apr 2016

Plitidepsin in combination with dexamethasone shows top-line results in Phase III multiple myeloma trial

PharmaMar today announced positive top-line results of its Phase III clinical trial -ADMYRE- with Aplidin (plitidepsin) in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma (MM).

2 Apr 2016

Drug Trial News

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

Binding Site to collarborate in iStopMM (Iceland Screens, Treats or Prevents Multiple Myeloma) trial

New clinical data highlights potential of AB-PA01 to treat P. aeruginosa infections in CF patients

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

Novel antibiotics to overcome antibacterial resistance

Pooled analysis from seven clinical studies demonstrates consistent efficacy for ceftazidime-avibactam in the treatment of multi-drug resistant gram-negative bacteria

AstraZeneca, MedImmune to present new clinical trial and scientific data on lung cancer treatments at ELCC 2016

Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

Wake Forest Baptist researchers looking for ways to keep older adults on their feet

Losmapimod drug fails to meet primary endpoint in clinical trial

Study elucidates potential benefits of antiarrhythmic drugs for out-of-hospital cardiac arrest patients

Two common approaches to post-operative AF equally safe, effective

New stem cell therapy significantly improves outcomes in patients with severe heart failure

Investigational drug provides no improved protection to patients with contrast-induced acute kidney injury

Evolocumab could be more effective than ezetimibe in lowering cholesterol in statin-intolerant patients

Researchers compare lipid-lowering efficacy for two nonstatin therapies in statin-intolerant patients

Investigational drug abaloparatide-SC may help increase bone mineral density in postmenopausal women

Cholesterol drug evacetrapib fails to reduce risk of cardiovascular events

Plitidepsin in combination with dexamethasone shows top-line results in Phase III multiple myeloma trial

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News